RGT
ARGENT BIOPHARMA LIMITED
$0.0280
▼ -6.67%
Market cap
$3M
Turnover
$3,494
Last price
$0.0280
Day change
-6.67%
Announcements
9
Range, past year
Open 0.087 · Low 0.028 · Now 0.028 · High 0.320
Open RGT in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.
RGT momentum and trend analysis
Our analysis
Independent analysis generated by Stock Trade Intelligence
as at 2026-10-13.
Momentum quality
17/100
Wyckoff phase
Accumulation25d
Trend stage
Neutral
1 Day
-6.7%
1 Week
-17.6%
1 Month
-9.7%
1 Year
-65.4%
RSI
39
Avg daily range
10.1%
ARGENT BIOPHARMA LIMITED scores 17 out of 100 for momentum quality, a reading rated very low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Neutral.
On the Wyckoff cycle it sits in Accumulation, where it has been for 25 trading days. The weekly timeframe reads Downtrend, which does not yet agree with the daily view.
Against the wider market it is currently underperforming and the institutional accumulation signal reads low.
Points to watch
- 60d drawdown -50.9%
- High volatility (ATR 10.1%)
- Thin liquidity
- Risk rating: Very High
- Composite downside risk elevated
RGT announcements
Recent price-sensitive releases.
- 2026-10-01 Execution of Loan Facility Agreement Debt Facility
- 2026-09-29 Argent Signs NLC Licence to Expand Antiviral Portfolio Progress Report
- 2026-08-31 Appendix 4E and 2026 Annual Report Annual Report | Top 20 shareholders | Preliminary Final Report | Full Year Accounts | Full Year Audit Review | Full Year Directors' Statement | Full Year Directors' Report
- 2026-08-26 FDA-CVM Establish INAD File for CannEpil Veterinary Program Progress Report
- 2026-08-06 US Veterinary Development Programme for CannEpil Commences Progress Report
- 2026-07-31 CannEpil Global Licence Expands into Veterinary Healthcare Progress Report
- 2026-07-28 Quarterly Activities/Appendix 4C Cash Flow Report Commitments Test Entity - Fourth Quarter Activity Report | Commitments Test Entity - Fourth Quarter Cashflow Report
More Health Care stocks
Most traded in the same sector.